<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360629</url>
  </required_header>
  <id_info>
    <org_study_id>V1.0</org_study_id>
    <nct_id>NCT04360629</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer</brief_title>
  <official_title>Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid has been used in surgery for more than 30 years. It's effect on reducing
      bleeding and blood transfusing has been demonstrated.

      In our hospital, the amount of cytorsductive surgery for ovarian cancer is big. During the
      perioperation , bleeding probability is high, and the supply of blood products is limited. In
      order to reduce bleeding, we're planning to use tranexamic acid in the operations.

      In this experiment, we will observe the efficacy of tranexamic acid in cytoreductive surgery
      for ovarian cancer, find the best dosage which can reach the desired effect, and the possible
      side-effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We performed a single blind, prospective, randomised control trial (RCT) . The patients
      randomised assigned to three groups. Low dose TXA, high dose TXA or a placebo of IV saline
      which will be infused prior to skin incision in patients undergoing elective cytorsductive
      surgery for ovarian cancer .

      Intraoperative blood loss will be estimated by the volume in the suction drains and by
      weighing the swabs. Postoperative blood loss will be estimated by the volume in the drains.

      The other secondary outcomes will be inclued perioperation transfusion volume, thromboembolic
      complications, ICU length of stay (LOS), hospital LOS, adverse thrombogenic events within 30
      days, 30-day all-cause readmission and so on.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>operative and postoperative blood loss</measure>
    <time_frame>up to 8 days</time_frame>
    <description>the amount of bleeding</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Advanced Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>high dose TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TXA will be given as a 20mg/kg bolus followed by infusion of 5mg/ kg/hr per our anesthesia protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TXA will be given as a 10mg/kg bolus followed by infusion of 1mg/ kg/hr per our anesthesia protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline will be given as a 4ml/kg bolus followed by infusion of 1ml/ kg/hr per our anesthesia protocolprotocol4ml/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic Acid will be given through central vein</description>
    <arm_group_label>high dose TXA</arm_group_label>
    <arm_group_label>low dose TXA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>normal saline will be given through central vein</description>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. sign the informed consent

          2. Aged 20-70 years

          3. ovarian cancer patients, staged IIIB - C or above

        3) ASA I - II

        Exclusion Criteria:

          1. tranexamic acid allergy

          2. pregnancy and lactation

          3. only lymph node metastasise

          4. history of mental disorder, immune system disorder

          5. history of epilepsy, dyschromatopsia

          6. arrhythmia

          7. history of renal insufficiency

          8. thrombosis related disease

          9. Hb &lt; 90 g/dL

         10. using anticoagulant drugs (not including aspirin discontinuation 1 week

         11. having participated in other clinical trials, or refusing to join the research.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xijun Yang, MD</last_name>
    <phone>13816063979</phone>
    <phone_ext>+86</phone_ext>
    <email>ppdxrq@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Zhang, PhD</last_name>
    <phone>21-64175590</phone>
    <phone_ext>86</phone_ext>
    <email>snapzhang@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Cancer Center, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Zakhari A, Sanders AP, Solnik MJ. Tranexamic acid in gynecologic surgery. Curr Med Res Opin. 2020 Mar;36(3):513-520. doi: 10.1080/03007995.2019.1708533. Epub 2020 Jan 6.</citation>
    <PMID>31865770</PMID>
  </results_reference>
  <results_reference>
    <citation>Kietpeerakool C, Supoken A, Laopaiboon M, Lumbiganon P. Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. Cochrane Database Syst Rev. 2016 Jan 23;(1):CD011732. doi: 10.1002/14651858.CD011732.pub2. Review.</citation>
    <PMID>26801659</PMID>
  </results_reference>
  <results_reference>
    <citation>Lundin ES, Johansson T, Zachrisson H, Leandersson U, Bäckman F, Falknäs L, Kjølhede P. Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study. Acta Obstet Gynecol Scand. 2014 Apr;93(4):335-44. doi: 10.1111/aogs.12333. Epub 2014 Feb 25.</citation>
    <PMID>24428857</PMID>
  </results_reference>
  <results_reference>
    <citation>Heyns M, Knight P, Steve AK, Yeung JK. A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis. Ann Surg. 2020 Mar 27. doi: 10.1097/SLA.0000000000003793. [Epub ahead of print]</citation>
    <PMID>32224739</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Director of the department of anaesthesiology, Shanghai cancer center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

